Premium
Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia
Author(s) -
Boultwood Jacqueline,
Pellagatti Andrea,
Watkins Fiona,
Campbell Lisa J.,
Esoof Noor,
Cross Nicholas C. P.,
Eagleton Helen,
Littlewood Tim J.,
Fidler Carrie,
Wainscoat James S.
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.05067.x
Subject(s) - myeloid leukaemia , chronic myeloid leukaemia , myelodysplastic syndromes , cancer research , myeloid , medicine , gene , myeloid leukemia , immunology , suppressor , biology , genetics , bone marrow
Summary The putative tumour suppressor gene gravin is down‐regulated in several solid tumours and is implicated in tumorigenesis. We have evaluated the expression levels of the gravin gene in the CD34 + /blast cells of a range of myeloid malignancies as compared with controls using real‐time quantitative polymerase chain reaction (PCR). Gravin was markedly down‐regulated in 41 of 41 patients with acute myeloid leukaemia (AML), nine of 10 patients with myelodysplastic syndromes (MDS) and 33 of 33 patients with chronic myeloid leukaemia (CML), of whom 24 were in blast crisis (BC). We have shown that gravin is consistently down‐regulated in the CD34 + /blast cells of myeloid malignancies and may play a role in the molecular pathogenesis of these disorders.